Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting
SALT LAKE CITY, March 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from 18 studies at the 2019 Annual Clinical Genetics Meeting (ACMG) being held April 2-6, 2019 in Seattle.
“We are excited to be presenting new data across multiple genetic tests at ACMG and to highlight our progress in advancing precision medicine for women,” said James Goldberg, M.D., board certified maternal fetal medicine specialist, medical geneticist and chief medical officer, Myriad Women’s Health. “With our continued research and collaborations, we strive to provide genetic information that helps patients and families with making their important healthcare decisions.”
Please visit Myriad Women’s Health at booth #632 to learn more about our leading portfolio of women’s health products. Follow Myriad on Twitter via @myriadgenetics and @MyrWomensHealth and keep up to date with meeting news and updates by using the hashtag #ACMGMtg19.
| Featured Research at 2019 ACMG | |||
| Product | Abstract | Presenting Author | Presentation Details |
| myRisk® Hereditary Cancer | Characteristics and Clinical Correlations of Somatic Mosaic Large Rearrangements Identified by Pan Cancer NGS Panel Test | Shujuan Pan | Podium (#166) April 3, 2019 12:15 p.m. – 1:15 p.m. |
| Clinical Utility of Testing for PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D: Management Changes and Patient Adherence to Provider Recommendations | Katie Johansen Taber | Poster: 197 April 4, 10:00 a.m. – 11:30 a.m. | |
| Fragile X Carrier Screening Accompanied by Genetic Consultation has Clinical Utility in Populations Beyond Those Recommended by Guidelines | Katie Johansen Taber | Poster: 903 Apr 4, 10:00 a.m.-11:30 a.m. | |
| A Data-Driven Approach for Determining Optimal Content for Expanded Carrier Screening Panels | Rotem Ben-Shachar | Poster: 924 Apr 4, 10:30 a.m.-12:00 p.m. | |
| Sequencing as a First-line Methodology for Cystic Fibrosis Carrier Screening | Dale Muzzey | Poster: 880 Apr 5, 10:30 a.m.-12:00 p.m. | |
| Distinct Scaling Between Positive Predictive Value and Panel Size for Expanded Carrier Screening, Noninvasive Prenatal Screening, and Hereditary Cancer Screening | Eerik Kaseniit | Poster: 892 Apr 5, 10:30 a.m.-12:00 p.m. | |
| Genetic-Ancestry Analysis on >95,000 Individuals Undergoing Expanded Carrier Screening Reveals Limitations of Ethnicity-Based Medical Guidelines | Eerik Kaseniit | Poster: 879 Apr 4, 10:00 a.m.-11:30 a.m. | |
| Foresight® Carrier Screen | Rare Recessive Diseases Enriched in the Ashkenazi Jewish Population but Omitted from Ethnicity-Specific Carrier Screening Guidelines | Eerik Kaseniit | Poster: 902 Apr 5, 10:30 a.m.-12:00 p.m. |
| Assessing Internal Consistency of Carrier Screening Guidelines Using Carrier Rates of 176 Conditions Across Seven Populations and 265,000 Individuals | Eerik Kaseniit | Poster: 940 Apr 5, 10:30 a.m.-12:00 p.m. | |
| Making the Case for Splice Indel Pathogenicity: A Comparison of Single Nucleotide and Insertion Variants at the +3 Site | Lea Gemmel | Poster: 678 Apr 5, 10:30 a.m.-11:30 a.m. | |
| Minimizing Results Delivery Time for Couples Undergoing Carrier Screening by Using a Tandem-Submission-with-Partner-Reflex (“Tandem Reflex”) Strategy | Eerik Kaseniit | Poster: 913 Apr 4, 10:30 a.m.-11:30 a.m. | |
| Application of a Severity Framework to 176 Conditions on an Expanded Carrier Screening Panel | Aishwarya Arjunan | Poster: 926 Apr 5, 10:30 a.m.-12:00 p.m. | |
| Meeting the Demand for Carrier Screening Results Disclosure and Patient Management | Aishwarya Arjunan | Poster: 616 Apr 5, 10:30 a.m.-12:00 p.m. | |
| Clarity from Discordance: Leveraging Fetal Fraction Reduces False Positives in Noninvasive Prenatal Screening. | Rotem Ben-Shachar | Poster: 927 Apr 4, 10:00 a.m.-11:30 a.m. | |
| Avoiding Unnecessary Trade-Offs: Clinical Experience for a Noninvasive Prenatal Screen with Both Low No-Call Rate and High Accuracy | Susan Hancock | Poster: 911 Apr 4, 10:00 a.m.-11:30 a.m. | |
| Prequel™ Prenatal Screen | Leveraging Whole Genome Sequencing in Noninvasive Prenatal Screening: A Case of Prader Willi Syndrome Due to Uniparental Disomy. | Susan Hancock | Poster: 922 Apr 5, 10:30 a.m.-12:00 p.m. |
| Clinical Experience for a Noninvasive Prenatal Screen in Assisted Reproductive Technology Pregnancies | Susan Hancock | Poster: 946 Apr 5, 10:30 a.m.-12:00 p.m. | |
| Rare Adds Up: Characterization of Mosaicism in Expanded Aneuploidy Analysis via Noninvasive Prenatal Screening | Albert Lee | Poster: 936 Apr 5, 10:30 a.m.-12:00 p.m. | |
About Myriad myRisk® Hereditary Cancer
The Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.
About Foresight® Carrier Screen
The Myriad Foresight Carrier Screen is designed to maximize detection of at-risk couples for serious, prevalent, and clinically-actionable conditions. Foresight has a rigorous disease selection that focuses on 175+ conditions that provides meaningful information to patients. Additionally, Foresight offers superior technology with unmatched detection rates for the vast majority of genes on the panel (>99% across ethnicities) which means patients can trust both positive and negative results.
About PrequelTM Prenatal Screen
The Myriad Prequel Prenatal Screen is a noninvasive prenatal screen that uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for chromosome abnormalities, such as Down syndrome. Prequel has been shown to be superior to screening methods that use maternal age, ultrasound and serum screening. Additionally, Prequel has a lower false-positive rate and false-negative rate than these other methods. The Prequel Prenatal Screen can be ordered with the Foresight Carrier Screen and offered to all women, including those with high body mass index, and ovum donor or a twin pregnancy.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five strategic imperatives: build upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Company’s presentation of new data for its expanded carrier and noninvasive prenatal screens being featured at the 2019 Annual Clinical Genetics Meeting April 2-6, 2019 in Seattle; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2018, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
